University Medical Center Ljubljana
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At University Medical Center Ljubljana, clinical research in Cardiovascular Diseases focuses on urgent bleeding management and improving care for patients who need surgery while taking anticoagulants. The studies are designed to evaluate whether new approaches can help control bleeding more effectively and support safer treatment decisions.
- Reversal of anticoagulation in patients taking factor Xa inhibitors
- Emergency surgery and procedure-related bleeding risk
- Testing a treatment approach to improve hemostasis and reduce bleeding complications
This work is especially relevant for people who require rapid, reliable bleeding control in high-risk surgical settings.
Hemic and Lymphatic Diseases
Research in Hemic and Lymphatic Diseases at the University Medical Center Ljubljana centers on Hemophilia A and Hemophilia B, with a strong focus on joint health and long-term disease management. The trials aim to better understand how prophylactic treatment may help preserve joint function and improve overall outcomes.
- Hemophilia A and B
- Joint status assessed with ultrasound
- Evaluating the effectiveness of preventive therapy for protecting joints
These studies support efforts to refine care for bleeding disorders and monitor how treatment may influence daily quality of life.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 21 therapeutic areas and 15 of 152 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 134 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 28 by active trials.
- 1Novartis Pharma AG5active
lock +27 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG12trials
lock +14 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 25 other sites in Slovenia
Therapeutic Area Benchmark — Slovenia
Select a therapeutic area to compare against other sites in Slovenia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Slovenia
Market Share
Country: Slovenia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in University Medical Center Ljubljana
lock Showing 1 of 83 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-week randomized, double-blind, placebo-controlled, multi-center Phase 2b study with a 52-week blinded extension and an optional open-label extension—assessing the safety and efficacy of frexalimab, a CD40L-antagonist monoclonal antibody, for the preservation of pancreatic β-cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy | Sanofi-Aventis Recherche & Developpement | Phase II | Not Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 152 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Sodium Chloride | 4 | Unknown | 2024-12-24 | 2026-04-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.